Videos
The American Society for Clinical Investigation (ASCI) honors Joseph C. Wu, MD, PhD, with the 2026 Stanley J. Korsmeyer Award. Dr. Wu is recognized for his seminal contributions to the understanding and application of human induced pluripotent stem cells in cardiovascular disease and his impactful mentorship of trainees. He is Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology. Dr. Wu was elected to the ASCI in 2012 (Councilor, 2014–2017). He is also a member of the Association of American Physicians (AAP) and National Academy of Medicine, as well as a fellow of the American Association for the Advancement of Science. ASCI President Dr. Priscilla Y. Hsue, Chief of the Division of Cardiology at UCLA, interviewed Dr. Wu at the AAP/ASCI/American Physician Scientists Association Joint Meeting in April 2026.
In this episode, Lauren Hablitz describes how the manuscript's findings suggest that reinforcing normal daily rhythmicity after stroke can markedly enhance neurological recovery, even when interventions are initiated several days after stroke onset.
The American Society for Clinical Investigation (ASCI) honors Frederick Kofi Korley, MD, PhD, with the 2026 ASCI/Louis W. Sullivan, MD, Award. Dr. Korley is recognized for his pioneering research in acute care diagnostics and therapeutics, and his impactful commitment to training physician-scientists. He is Professor and Associate Chair for Research in Emergency Medicine at the University of Michigan as well as Scientific Director of the Massey TBI [traumatic brain injury] Grand Challenge, sponsored by the University of Michigan Weil Institute. Dr. Korley chairs the American College of Emergency Physicians TBI expert panel and was the 2021 recipient of the Society of Academic Emergency Medicine Mid-Career Investigator Award. He was elected to the ASCI in 2024. ASCI President-Elect Dr. Stephen Y. Chan, Vitalant Chair in Vascular Medicine and Professor of Medicine and Director of the Vascular Medicine Institute at the University of Pittsburgh School of Medicine and UPMC, interviewed Dr. Korley at the AAP/ASCI/APSA Joint Meeting in Chicago in April 2026.
In this episode, James Crowe describes how these studies support the development of CCHFV countermeasures to induce protection against GP38 in vivo.
In this episode, Fumihiko Urano describes how the manuscript reports 24- and 48-week results from the ongoing HELIOS trial (ClinicalTrials.gov NCT05676034), a single-center, single-arm, open-label, phase II trial of PB&TURSO. Collectively, these results support continued development of PB&TURSO.
Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)